We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Pfizer (PFE - Free Report) closed at $42.76, marking a +0.66% move from the previous day. This change outpaced the S&P 500's 0.61% gain on the day. At the same time, the Dow added 0.71%, and the tech-heavy Nasdaq gained 0.53%.
Prior to today's trading, shares of the drugmaker had gained 3.74% over the past month. This has outpaced the Medical sector's loss of 1.29% and the S&P 500's loss of 3.77% in that time.
PFE will be looking to display strength as it nears its next earnings release. In that report, analysts expect PFE to post earnings of $0.78 per share. This would mark a year-over-year decline of 3.7%. Meanwhile, our latest consensus estimate is calling for revenue of $13.42 billion, down 0.31% from the prior-year quarter.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.89 per share and revenue of $52.86 billion. These results would represent year-over-year changes of -3.67% and -1.46%, respectively.
Investors might also notice recent changes to analyst estimates for PFE. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.17% higher. PFE is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, PFE is currently trading at a Forward P/E ratio of 14.7. This represents a premium compared to its industry's average Forward P/E of 14.36.
Investors should also note that PFE has a PEG ratio of 2.45 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 57, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Pfizer (PFE - Free Report) closed at $42.76, marking a +0.66% move from the previous day. This change outpaced the S&P 500's 0.61% gain on the day. At the same time, the Dow added 0.71%, and the tech-heavy Nasdaq gained 0.53%.
Prior to today's trading, shares of the drugmaker had gained 3.74% over the past month. This has outpaced the Medical sector's loss of 1.29% and the S&P 500's loss of 3.77% in that time.
PFE will be looking to display strength as it nears its next earnings release. In that report, analysts expect PFE to post earnings of $0.78 per share. This would mark a year-over-year decline of 3.7%. Meanwhile, our latest consensus estimate is calling for revenue of $13.42 billion, down 0.31% from the prior-year quarter.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.89 per share and revenue of $52.86 billion. These results would represent year-over-year changes of -3.67% and -1.46%, respectively.
Investors might also notice recent changes to analyst estimates for PFE. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.17% higher. PFE is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, PFE is currently trading at a Forward P/E ratio of 14.7. This represents a premium compared to its industry's average Forward P/E of 14.36.
Investors should also note that PFE has a PEG ratio of 2.45 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 57, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.